A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose,
and demonstrate its clinical value for treating COVID-19 in adult ambulatory patients